

RESEARCH PAPER

Production of *Plasmodium vivax* enolase in *Escherichia coli* and its protective properties

Chao Zhang^{a,b}, Yaping Gu^a, Jianxia Tang^a, Feng Lu^a, Yuanyuan Cao^a, Huayun Zhou^a, Guoding Zhu^a, Jun Cao^{a,b}, and Qi Gao^a

^aKey Laboratory on Technology for Disease Prevention and Control (Ministry of Health), Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Jiangsu Institute of Parasitic Diseases, Wuxi, Jiangsu, China; ^bPublic Health Research Center, Jiangnan University, Wuxi, China

ABSTRACT

Plasmodium vivax predominates in South-East Asia and the American continent, causes significant morbidity and inflicts a huge socioeconomic burden. Sequencing completion of the *Plasmodium vivax* genome and transcriptome provides the chance to identify antigens. Enolase is the eighth enzyme in the glycolytic pathway, which, apart from its glycolytic function, also possess antigenic properties and is present on the cell wall of many invasive organisms, such as *Candida albicans*. In order to assess whether enolase of *Plasmodium vivax* is also antigenic, in this study, we first reported the expression and purification of recombinant *Plasmodium vivax* enolase (r-Pven) in *Escherichia coli*, using prokaryotic expression vector. The r-Pven was expressed in soluble form in *E. coli*, and the expression was verified by SDS-PAGE and western blotting analysis. The r-Pven was purified to 90% purity by nickel–nitrilotriacetic acid (Ni²⁺–NTA) resin chromatography. For reactivity with r-Pven, compared with the average values of the reactivity of control serum samples, the average values of the reactivity of 99 individual serums from *vivax* malaria patients appeared higher, and there was significant difference between them ($p=0.0117<0.05$). Mice anti-r-Pven antibodies inhibited the growth of *in vitro* cultures of *P. falciparum*. Mice immunized with r-Pven showed protection against a challenge with the mouse malarial parasite *Plasmodium berghei*. The antibodies raised against r-Pven were specific for *Plasmodium* and did not react to the host tissues. These observations established *Plasmodium vivax* enolase to be a potential protective antigen.

ARTICLE HISTORY

Received 18 April 2016
Revised 9 June 2016
Accepted 27 June 2016

KEYWORDS

Enolase; Malaria;
Plasmodium vivax;
Prokaryotic expression;
Vaccine candidate

Introduction

The malaria, continues an important public health problem in the world, which affects mainly developing countries, including Africa, Asia and Latin America. By the World Health Organization, it was estimated that there were 214 million cases of malaria worldwide in 2015.¹ Among these cases, there were 13.8 million cases caused by *Plasmodium vivax*, which predominated in South-East Asia and the American continent where there were more than 50% of malaria cases.¹ Despite intensive efforts to control the malaria epidemic, the proportion of cases caused by *P. vivax* is increasing, and current prophylaxis and drug treatments still proved insufficient.²

Sequencing completion of the *Plasmodium vivax* genome and transcriptome provides the chance to identify antigens. So far, several proteins, including merozoite surface protein 1 (MSP1), and apical membrane antigen 1 (AMA1), have shown antigens and/or potential vaccine candidates, but developing an effective malaria vaccine has remained an incredibly difficult challenge.³

Enolase, as a major immunostimulatory protein of visceral leishmaniasis,⁴ is present on the cell surface of many organisms,⁵ could play a protective role in *Candida albicans* infection,⁶ and has recently been reported as a potential vaccine candidate against

Chlamydia pneumoniae.⁷ Therefore, for investigating whether *Plasmodium vivax* Enolase (r-Pven) could play a protective role against *Plasmodium vivax* infection, we decided to produce *Plasmodium vivax* Enolase in *Escherichia coli* and examine the immunogenic and protective properties of Pven.

In this study, we had successfully expressed *P. vivax* Enolase in *Escherichia coli*, examined the immunogenic properties of Pven in sera of *P. vivax* malaria patients in regions of China, where malaria is endemic, and demonstrated the growth-inhibitory properties of anti-enolase antibodies, and the protective capacity of recombinant Pven in mice challenged with the mouse malaria parasite *Plasmodium berghei*.

Results

Plasmid Construction of plasmodium vivax enolase (r-Pven)

The construct for Enolase expression, containing a His-tag for affinity purification, was depicted in Figure 1. The recombinant plasmid pET28α- Pven protein sequence was verified by DNA sequencing (Nanjing Genscript Bio. Co. Ltd). The correct construct was transformed into the expression host *E. coli* BL21

CONTACT Jun Cao  caojuncn@hotmail.com  Jiangsu Institute of Parasitic Diseases, Wuxi, Jiangsu 214064, China; Qi Gao  gaoqi54@hotmail.com  Jiangsu Institute of Parasitic Diseases, Wuxi, Jiangsu 214064, China.

Color versions of one or more of the figures in the article can be found online at www.tandfonline.com/khvi.

 Supplemental data for this article can be accessed on the publisher's website.




Figure 1. Schematic illustration of Plasmid Construction of *Plasmodium vivax* Enolase (r-Pven) in pET28 α prokaryotic expression vector with kanamycin resistant gene. (A) For the cDNA encoding Pven protein, the method of overlapping polymerase chain reaction (overlap PCR) was used, with 3 primers P1, P2, and P3; (B) Schematic representation of the expression vector pET28 α - r-Pven.

(DE3). As shown in Figure 2, there was an obvious protein band after IPTG induction, which could be detected using the western blotting method with anti-6 \times His tag antibody. The apparent molecular weight of the r-Pven protein was about 50 kDa.

Expression, purification and identification of r-Pven

As described above, after IPTG induction, Ni-NTA resin was used for r-Pven protein purification. Most of the proteins without 6 \times His tags were removed from the Ni-NTA resin using washing buffer containing 20 mM imidazole, and the 6 \times His-tagged r-Pven was eluted with more than 90% purity using elution buffer containing 250 mM imidazole (Fig. 2). The purity was estimated through SDS-PAGE gels stained using Coomassie Blue, and the western blotting method was used to further confirm the expression of r-Pven.

Reactivity of r-Pven with seras from plasmodium vivax malaria patients

The well-type amine array was carried out with r-Pven as the substrate, using serum from *Plasmodium vivax* malaria




Figure 2. The expression analysis of recombinant *Plasmodium vivax* Enolase (r-Pven) expressed in *E. coli* BL21. The expression analysis using 12% SDS-PAGE and Western blotting. Marker: Protein molecular weight marker; lane 1: Crude cells extracts of uninduced *E. coli* BL21 containing pET28 α - r-Pven; lane 2: Crude cells extracts of induced *E. coli* BL21 containing pET28 α - r-Pven; lane 3: Sonicated supernatant of induced *E. coli* BL21 containing pET28 α - r-Pven; lane 4: Sonicated precipitation of induced *E. coli* BL21 containing pET28 α - r-Pven; lane 5: Purified supernatant on Ni²⁺- IDA His-bind resin; lane 6: Purified supernatant examined using the western blotting.




Figure 3. Map of sampling sites of serums from *Plasmodium vivax* malaria patients in Anhui Province, China (A) and Reactivity of r-Pven with seras from *Plasmodium vivax* malaria patients (B). Notes: MFI, mean fluorescence intensity.

patients, along with control serum samples, who had not been exposed to malaria. The individual reactivity of serum samples from patients was shown in Figure 3B. Compared with the average values of the reactivity of control serum samples, the average values of the reactivity of serum from vivax malaria patients appeared higher, and there was significant difference between them ($p=0.0117 < 0.05$). These results suggested that anti-Pv enolase antibodies were prevalent among *Plasmodium vivax* malaria patients in China.

ELISA, immunoblotting and growth inhibition assays

In order to examine the antibody titer of the antibodies raised in mice against r-Pven, an ELISA was carried out. As shown in

Figure 4A, anti-r-Pven antibody titers were greater than 1:300,000, and even at 1: 500,000, as shown in Figure 4B, the reactivity color of anti-r-Pven antibody could be examined.

In order to test whether antibodies against r-Pven could inhibit parasite growth, the specificity of the antibodies raised in mice against r-Pven was examined. Whole-cell extracts prepared from *P. falciparum* and from human erythrocyte were subjected to SDS-PAGE and blotted on a membrane, which was treated with anti-r-Pven antibodies (Fig. 5A). The antibodies raised in mice against r-Pven did not react with human erythrocyte proteins. The immunoblotting data showed the specificity of the anti-r-Pven antibodies toward Pfen.

Anti-plasmodial assay was then performed using *P. falciparum* asexual stages cultures of *Plasmodium falciparum*, which




Figure 4. Antibody titer was determined for the prepared antisera according to the indirect ELISA method. Test results about anti-r-Pven antibody titers (A) and the corresponding reactivity color of anti-r-Pven antibody (B).




Figure 5. Inhibition of anti-r-Pven antibody against *P. falciparum* FCC1/HN. (A) Whole-cell extracts prepared from *P. falciparum* and from human were subjected to SDS-PAGE and blotted on a membrane, and the blot was treated with anti-r-Pven antibodies; (B) Anti-plasmodial assay of anti-r-Pven antibody.

were exposed to anti-r-Pven antibodies. As shown in **Figure 5B**, the anti-r-Pven antibodies could reduce the parasite density over the time course of the experiment in relation to controls.

At 72 hours post-treatment, the maximum inhibitory effect was observed. These results suggested that the antibodies against Pven could inhibit the growth of the parasites.




Figure 6. Vaccination study using r-Pfen as an immunogen. (A) Whole-cell extracts prepared from *Plasmodium berghei* and from mice were subjected to SDS-PAGE and blotted on a membrane, and the blot was treated with anti-r-Pven antibodies; (B) The average parasitemia for each group of mice were shown; (C) The survival pattern for each group of mice were shown.

Vaccination studies with r-Pven in mice. Next, we tried to evaluate the ability of the Pven to protect mice against a challenge with mouse malaria parasites. In order to demonstrate that the antibodies raised in mice against r-Pven could react with *Plasmodium berghei* enolase, whole-cell extracts prepared from *P. berghei* and from mice were subjected to SDS-PAGE and blotted on a membrane, which was treated with anti-r-Pven antibodies (Fig. 6A). The antibodies raised in mice against r-Pven did not react with mice erythrocyte proteins. The immunoblotting data confirmed the specificity of the anti-r-Pven antibodies toward *P. berghei* enolase.

Then, we examined the effects of immunization of mice with r-Pven, followed by a challenge with mouse malaria parasites *P. berghei*. As shown in Fig. 6B, the reduction in parasitemia correlated with the antibody titer present in each mouse. Figure 6C showed the survival profile of the mice. The immunized mice also had a significantly longer survival period. These data suggested that the protection was specific for r-Pven.

Discussion

In this study, we have shown that the *Plasmodium vivax* enolase protein was immunogenic and that anti-Pv enolase antibodies could protect against the malarial parasite. Protective anti-r-Pven antibodies raised in animals were specific for *Plasmodium*. These reacted with the enolase from both human and murine *Plasmodium* species but did not cross-react with the host proteins. So, Pven possesses the properties suitable for a potential candidate malaria vaccine antigen.

In rodent malaria challenge studies, 2 leading vaccine candidates, MSP-119 and AMA-1 (apical membrane antigen 1), showed protection only from homologous, but not heterologous challenge.^{8,9} In several other studies, it has been reported that protection acrossed a limited number of strains.^{9,10} A chimeric antigens vaccine including multiple epitopes from different *Plasmodium* antigens is considered to be an ideal way to address these difficulties. r-Pven was maybe one such candidate. Although it was shown that the *Plasmodium* enolase protein had considerable homology with the human ortholog, it had certain novel plant-like features,¹¹ and distinct structural differences.¹² In this study, the lack of cross-reactivity of anti-r-Pven with host enolases had been shown by methods of immunoblotting.

Enolase was identified as a multifunctional protein, involved in the pathogenicity in several *Streptococcus* by binding the plasminogen of an infected host,^{13,14} including the bacterial migration across the mammalian extracellular matrix,¹⁵ and an important antigen using immunoproteomics analysis of extracellular and cell-wall associated proteins of SS2.^{16,17} So far, several reports have shown that the enolase of several types of G+ bacteria could activate plasminogen and then the surface-bound plasmin could degrade extracellular matrix and laminin, and facilitate penetration of the organism through reconstituted basement membrane,¹⁸ suggesting that anti-Enolase antibodies could be important as an adjunctive vaccine.¹⁹ However, the potential of enolase developed as novel vaccine antigen remained to be convinced.

Conclusion

In this study, we had shown that a housekeeping enolase protein of *Plasmodium vivax* could protect mice against malaria. An effective malaria vaccine has been shown to be difficult to achieve for several reasons, predominant among which are antigenic variation and diversity. An additional problem is the emerging resistance of the parasite to most antimalarial drugs. Thus, it would be worthwhile to evaluate enolase, a protein critical to the survival of the parasite, for the immunoprophylactic and immunotherapeutic control of malaria. Enolases, which have been well characterized for their catalytic function in glucose metabolism, are no longer considered to be the house-keeping enzymes only. Some of the more interesting and challenging issues, regarding enolase multi-function that need to be addressed are (i) the mechanism of its export to the cell surface, (ii) the role of posttranslational modifications of enolase and implications on its subcellular distribution and function. Investigations of these subjects would provide insights into its important role and it would make this protein an interesting drug target.

Materials and methods

Human serum samples Human serum samples were collected in areas of Anhui province, China. 99 individual serums from *Plasmodium vivax* malaria patients were selected and tested for reactivity with r-Pven protein. The samples were collected with appropriate ethical clearance after obtaining subject consent. Approximately 0.1 to 1.0 ml of blood was collected using heparinized capillaries or tubes. The geographical distribution, sampling time, and parasitemia of *Plasmodium vivax* malaria patients were shown in Table S1.

Construction of pET28 α -pven protein expressing vector

To obtain the cDNA encoding Pven protein, the method of overlapping polymerase chain reaction (overlap PCR) was used. Three primers for PCR were designed as follows based on the Pven sequence:

P1 -(sense): 5'-cggcCATATGccccacgtaattactctgtatttctgccctgaaattttgg

(box = NdeI site)

P2 -(sense): 5'-gtatttctgccctgaaattttggactcccgaggaaaccaaccg

P3 -(anti-sense): 5'-agcaGCGGCCGCTcaacttaattggtcctaatttc

(box = NotI site)

The primers P1 and P2 had the overlapping sequence (underlined), and the primers P2 and P3 were used to amplify the part of Exon 1 and Exon 2 from genomic DNA of *Plasmodium vivax*, which was extracted from whole blood, using QIAamp DNA Blood Mini Kit (QIAGEN, Germany). After the first round of PCR, a second round of PCR was performed using the PCR products of the first round as template with the primers P1 and P3, which resulted in the cDNA encoding Pven protein. The PCR product was then digested by *NdeI* and *NotI* and was inserted in frame into the pET28 α expression vector (Novagen) (Fig. 1). The recombinant vector was transformed into the competent DH5 α cells for propagation of the

recombinant plasmid. The recombinant plasmid pET28 α -Pven was confirmed, using restriction endonucleases digestion and sequencing.

Expression and purification of plasmodium vivax enolase (r-Pven)

The constructed recombinant plasmid pET28 α -Pven was transformed into competent *E. coli* BL21. One colony of *E. coli* BL21 harboring the plasmid pET28 α -Pven was grown overnight at 37°C in 10 ml of LB medium supplemented with kanamycin (30 μ g/ml). The whole culture was inoculated into 1 L fresh LB medium and grown to an OD₆₀₀ of 0.6 at 37°C. Fusion protein expression was initiated with the addition of IPTG to 1 mM. After 6 h induction, cells were collected using centrifugation at 7,000 g for 10 min at 4°C, resuspended in binding buffer (20 mM Tris/HCl, 0.5 M NaCl, and 5 mM imidazole pH 7.9), and lysed on ice using sonication at 400 W for 100 cycles (5 s working, 5 s free). The recombinant Plasmodium vivax Enolase in the supernatant of the cell lysate was then purified using Ni-NTA affinity chromatography, according to our previously published method.²⁰

SDS-PAGE and western blotting analyses

The SDS-PAGE analysis was performed, according to Laemmli, using 12% polyacrylamide gels.²⁰ The total expression protein samples from cell lysates after induction were mixed with equivalent sample buffer (125 mM Tris-HCl, pH 6.8, 20% glycerol, 4% SDS, 0.005% bromophenol blue, and 10% 2-mercaptoethanol). Gels were stained with Coomassie brilliant blue R-250.

For western blotting analysis, the same protein sample was separated on a 12% polyacrylamide gel under reducing conditions and then transferred to a polyvinylidene difluoride (PVDF) membrane (Roche Applied Science). The western blotting was performed as described.²⁰ The rabbit IgG secondary antibody was used against His-tag primary antibody (Novagen). The blots were developed using TMB immunoblotting system.

Reactivity of r-Pven with sera from plasmodium vivax malaria patients

99 individual sera from vivax malaria patients were used in well-type amine arrays. The procedure was performed as described in a previous report,⁹ and the fluorescence intensities of array spots were quantified by the fixed-circle method using ScanArray Express software (version 4.0; PerkinElmer, Boston, MA, USA).^{21,22} The cut-off value was calculated as the mean fluorescence intensity (MFI) value of reactivity of each patient's serum with r-Pven.

Vaccination studies with r-Pven in mice. Experiments were performed on 3 groups of 8-week-old male Kunming mice (5 mice per group), which were purchased from Beijing Animal Experimental Center, China. The r-Pven was rapidly mixed with an equal volume of Quick Antibody (Kangbiquan Inc., China), a novel water-solubility immunoadjuvant without emulsification to distinguish from the Freund's adjuvant. The resulting mixture was transferred to a 1 mL-syringe and was then injected into the hind leg muscle of a mouse. After 3 weeks,

the antigen was dissolved in Quick Antibody adjuvant to conduct a boosting injection in the same (the first injection was 100 μ g of r-Pven, followed by 100 μ g for the one booster). In one control group, mice were injected in parallel with the adjuvant. The other control group received no injections. After three immunizations, the antibody titers against r-Pven were monitored. Mice having anti-r-Pven antibody titers greater than 1:300,000 were then challenged with Plasmodium berghei (10⁶ parasites per mouse), and parasitemia was monitored daily. Results of the parasitemia profiles were statistically analyzed using one-way analysis of variance (GraphPad InStat, San Diego, CA). Laboratory animal handling and experimental procedures were performed in accordance with the requirements of Provisions and General Recommendation of Chinese Experimental Animals Administration Legislation.

ELISA

Antibody titer was determined for the prepared antisera according to the indirect ELISA method.²³ To each well of a 96 well microplate, 100 μ L of the pure SUMO-MT solution (10 μ g/mL) dissolved in the coating buffer (0.5 M Na₂CO₃/NaHCO₃, pH 9.6) was added and the microplate was set still at 4°C overnight. The antiserum was diluted in 1,000–2,048,000 folds with 1 \times pH 7.4 PBS. The incubation with the secondary antibody was carried out with 100 μ L of a 5,000 fold diluted horseradish peroxidase-conjugated goat antibody (GeneTex, USA) diluted with PBSTB (1 \times pH 7.4 PBS, 1% BSA, 0.1% Tween). Then added 100 μ L substrate mixture of o-phenylenediamine (OPD) (Amresco, USA) per well and incubated for 30 min at room temperature. Finally, 100 μ L of 2 M H₂SO₄ was added to stop the reaction and quantification was performed with a microplate reader (TECAN Infinite M200, Switzerland) at 492 nm.

Anti-plasmodial assay

The *P. falciparum* FCC1/HN strain was used for the assay. The FCC1/HN line was isolated from Hainan Island, China.²⁴ The strain was cultured in human erythrocytes type A+ at 5% hematocrit. The strain was cultured in RPMI (Gibco) medium supplemented with HEPES 25 mM, glutamine 2 mM, glucose 2 g/l, NaHCO₃ 2 g/l, hypoxanthine 29.25 mg/l, gentamicin 60 mg/l and Albumax 1.6% at pH 7.4. Cultures were kept in 96% nitrogen, 3% CO₂ and 1% oxygen atmosphere at 37°C, and fresh medium was added every 24 h.²⁵

Cultured human erythrocytes at 1.5% of parasitemia (*P. falciparum* asexual stages) were cultured in the presence of anti-r-Pven antibodies for 24, 48 and 72 h. Every 24 h, the medium was discharged, and fresh medium with the appropriate anti-r-Pven antibodies concentration was added. The percentage of infected red blood cells was determined by microscopic examination of thin blood films stained with Giemsa. Controls with preimmune antiserum and nontreated infected erythrocytes were included.

Statistical analysis

Results were expressed as mean+SD from at least 3 independent experiments. Statistical analysis was performed according

to Student's t-test by one-way analysis of variance. Significant difference was taken as $P < 0.05$.

Disclosure of potential conflicts of interest

The authors declare that there are no conflicts of interest.

Funding

This work was supported by grants from National Nature Science Foundation of China (81101276 and 81271870), Nature Science Foundation of Jiangsu Province (BK2011163 and BK20150001), Jiangsu Science and Technology Department (BM2015024), and Jiangsu Health Department (X201127).

Author contributions

Conceived and designed the experiments: Chao Zhang, Jun Cao, Qi Gao. Performed the experiments: Chao Zhang, Yaping Gu, Jianxia Tang, Feng Lu Yuan Yuan Cao. Analyzed the data: Chao Zhang, Huayun Zhou, Guodong Zhu, Jun Cao, Qi Gao. Wrote the paper: Chao Zhang, Jun Cao, Qi Gao.

References

- Arévalo-Herrera M, Lopez-Perez M, Dotsey E, Jain A, Rubiano K, Felgner PL, Davies DH, Herrera S. Antibody Profiling in Naïve and Semi-immune Individuals Experimentally Challenged with *Plasmodium vivax* Sporozoites. *PLoS Negl Trop Dis* 2016; 10(3):e0004563; <http://dx.doi.org/10.1371/journal.pntd.0004563>
- Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of *Plasmodium vivax*, a neglected human malaria parasite. *Lancet Infect Dis* 2009; 9:555-66; PMID:19695492; [http://dx.doi.org/10.1016/S1473-3099\(09\)70177-X](http://dx.doi.org/10.1016/S1473-3099(09)70177-X)
- Girard MP, Reed ZH, Friede M, Kieny MP. A review of human vaccine research and development: malaria. *Vaccine* 2007; 25:1567-80; PMID:17045367; <http://dx.doi.org/10.1016/j.vaccine.2006.09.074>
- Gupta SK, Sisodia BS, Sinha S, Hajela K, Naik S, Shasany AK, Dube A. Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of *Leishmania donovani* promastigotes. *Proteomics* 2007; 7:816-23; PMID:17295358; <http://dx.doi.org/10.1002/pmic.200600725>
- Ángels DR, Anna RB, Ana GM, Roser LA. α -Enolase, a Multifunctional Protein: Its Role on Pathophysiological Situations. *J Biomed Biotechnol* 2012; 2012:156795; PMID:23118496
- Montagnoli C, Sandini S, Bacci A, Romani L, La Valle R. Immunogenicity and protective effect of recombinant enolase of *Candida albicans* in a murine model of systemic candidiasis. *Med Mycol* 2004; 42:319-24; PMID:15473356; <http://dx.doi.org/10.1080/13693780310001644653>
- Finco O, Bonci A, Agnusdei M, Scarselli M, Petracca R, Norais N, Ferrari G, Garaguso I, Donati M, Sambri V, et al. Identification of new potential vaccine candidates against *Chlamydia pneumoniae* by multiple screenings. *Vaccine* 2005; 23:1178-88; PMID:15629361; <http://dx.doi.org/10.1016/j.vaccine.2004.07.045>
- Renia L, Ling IT, Marussig M, Miltgen F, Holder AA, Mazier D. Immunization with a recombinant C-terminal fragment of *Plasmodium yoelii* merozoite surface protein 1 protects mice against homologous but not heterologous *P. yoelii* sporozoite challenge. *Infect Immun* 1997; 65:4419-23; PMID:9353014
- Crewther PE, Matthew ML, Flegg RH, Anders RF. Protective immune responses to apical membrane antigen 1 of *Plasmodium chabaudi* involve recognition of strain-specific epitopes. *Infect Immun* 1996; 64:3310-7; PMID:8757869
- Majarian WR, Daly TM, Weidanz WP, Long CA. Passive immunization against murine malaria with an IgG3 monoclonal antibody. *J Immunol* 1984; 132:3131-7; PMID:6725950
- Narum DL, Ogun SA, Batchelor AH, Holder AA. Passive immunization with a multicomponent vaccine against conserved domains of apical membrane antigen 1 and 235-kdalton rho-1 proteins protects mice against *Plasmodium yoelii* blood-stage challenge infection. *Infect Immun* 2006; 74:5529-36; PMID:16988228; <http://dx.doi.org/10.1128/IAI.00573-06>
- Sato K, Kano S, Matsumoto Y, Glanarongran R, Krudsood S, Loor-eesuwan S, Aikawa M, Suzuki M. Application of yeast enolase as antigen for immunodiagnosis of malaria. *Southeast Asian J Trop Med Public Health* 2000; 31:79-84; PMID:11414465
- Jones MN, Holt RG. Cloning and characterization of an α -enolase of the oral pathogen *Streptococcus mutans* that binds human plasminogen. *Biochem Biophys Res Commun* 2007; 364(4):924-9; PMID:17964283; <http://dx.doi.org/10.1016/j.bbrc.2007.10.098>
- Veiga-Malta I, Duarte M, Dinis M, Tavares D, Videira A, Ferreira P. Enolase from *Streptococcus sobrinus* is an immunosuppressive protein. *Cell Microbiol* 2004; 6(1):79-88; PMID:14678332; <http://dx.doi.org/10.1046/j.1462-5822.2003.00344.x>
- Pancholi V. Multifunctional α -enolase: its role in diseases. *Cell Mol Life Sci* 2001; 58(7):902-20; PMID:11497239; <http://dx.doi.org/10.1007/PL00000910>
- Jing HB, Yuan J, Wang J, Yuan Y, Zhu L, Liu XK, Zheng YL, Wei KH, Zhang XM, Geng HR, et al. Proteome analysis of *Streptococcus suis* serotype 2. *Proteomics* 2008; 8(2):333-49; PMID:18081191; <http://dx.doi.org/10.1002/pmic.200600930>
- Zhang A, Xie C, Chen H, Jin M. Identification of immunogenic cell wall-associated proteins of *Streptococcus suis* serotype 2. *Proteomics* 2008; 8(17):3506-15; PMID:18686301; <http://dx.doi.org/10.1002/pmic.200800007>
- Eberhard T, Kronvall G, Ullberg M. Surface bound plasmin promotes migration of *Streptococcus pneumoniae* through reconstituted basement membranes. *Microb Pathog* 1999; 26(3):175-81; PMID:10089158; <http://dx.doi.org/10.1006/mpat.1998.0262>
- Whiting GC, Evans JT, Patel S, Gillespie SH. Purification of native α -enolase from *Streptococcus pneumoniae* that binds plasminogen and is immunogenic. *J Med Microbiol* 2002; 51(10):837-43; PMID:12435062; <http://dx.doi.org/10.1099/0022-1317-51-10-837>
- Zhang C, He X, Gu Y, Zhou H, Cao J, Gao Q. Recombinant Scorpion Produced Using SUMO Fusion Partner in *Escherichia coli* Has the Activities against Clinically Isolated Bacteria and Inhibits the *Plasmodium falciparum* Parasitemia In Vitro. *PLoS ONE* 2014; 9(7):e103456; PMID:25068263; <http://dx.doi.org/10.1371/journal.pone.0103456>
- Chen JH, Jung JW, Wang Y, Ha KS, Lu F, Lim CS, Takeo S, Tsuboi T, Han ET. Immunoproteomics profiling of blood stage *Plasmodium vivax* infection by high-throughput screening assays. *J Proteome Res* 2010; 9:6479-89; PMID:20949973; <http://dx.doi.org/10.1021/pr100705g>
- Lu F, Li J, Wang B, Cheng Y, Kong DH, Cui L, Ha KS, Sattabongkot J, Tsuboi T, Han ET. Profiling the humoral immune responses to *Plasmodium vivax* infection and identification of candidate immunogenic rho-1-associated membrane antigen (RAMA). *J Proteomics* 2014; 102:66-82; PMID:24607491; <http://dx.doi.org/10.1016/j.jprot.2014.02.029>
- He Y, Ma W, Li Y, Liu J, Jing W, Wang L. Expression of metallothionein of freshwater crab (*Sinopotamon henanense*) in *Escherichia coli* enhances tolerance and accumulation of zinc, copper and cadmium. *Ecotoxicology* 2014; 23(1):56-64; PMID:24276409; <http://dx.doi.org/10.1007/s10646-013-1151-0>
- Pan WQ, Huang DQ, Zhang QF, Li Qu, Zhang DM, Xue X, Qian F. Fusion of Two Malaria Vaccine Candidate Antigens Enhances Product Yield, Immunogenicity, and Antibody-Mediated Inhibition of Parasite Growth In Vitro. *J Immunol* 2004; 172:6167-74; PMID:15128804; <http://dx.doi.org/10.4049/jimmunol.172.10.6167>
- Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science* 1976; 193:673-5; PMID:781840; <http://dx.doi.org/10.1126/science.781840>